Dosing

Transition begins patient dosing in phase 2 study of SARM drug candidate TT701
The phase 2 study will evaluate the efficacy and safety of TT701 in improving the symptoms of androgen deficiency (sexual symptoms, fatigue/low vitality, and physical dysfunction) in men with prostate cancer who have undergone radical prostatectomy for ... [...]
4
Like
Save
OPKO Health Announces Dosing of First Subject in Phase 1 Clinical Study of a …
... Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office ... [...]
1
Like
Save